Current possibilities and prospects for the first line of therapy for peripheral T-cell lymphomas
Kolgotina A.G., Filatova L.V., Zyuzgin I.S., Kramynin L.A., Elkhova S.S., Zverkova A.A., Volchenkov S.A., Kolupaev N.S., Eliseeva A.O., Kodrul E.N., Semiglazova T.Yu.
Peripheral T-cell lymphomas (PTCL) are a group of rare aggressive non-Hodgkin’s lymphomas with an unfavorable prognosis. The 5-year overall survival rate is 30–50% (with the exception of ALK-positive anaplastic large-cell lymphoma, at 77–85%). Due to high hematologic toxicity and efficacy comparable to CHOP, antifolates, alemtuzumab, hypomethylating agents, histone deacetylase inhibitors, and lenalidomide have not been adopted as first-line therapy. Modern first-line therapy regimens (CHOP, CHOEP, CHP-Bv, CHEP-Bv) are based on the results of a randomized phase III trial ECHELON-2, which demonstrated the advantage of Bv-CHP over CHOP in CD30+ PTCL, as well as a number of large population-based retrospective studies, who showed the potential benefit of adding etoposide to CHOP. New data on the biological heterogeneity of PTCL may influence the choice of therapy in the future. It was found that PTCL from T-follicular helpers are more sensitive to hypomethylating agents and JAK inhibitors. The evidence base for the effectiveness of brentuximab vedotin in low or negative CD30 expression is growing. This article is devoted to the main first-line chemotherapy regimens and possible future treatments for PTCL, taking into account new data.
For citations: Kolgotina A.G., Filatova L.V., Zyuzgin I.S., Kramynin L.A., Elkhova S.S., Zverkova A.A., Volchenkov S.A., Kolupaev N.S., Eliseeva A.O., Kodrul E.N., Semiglazova T.Yu. Current possibilities and prospects for the first line of therapy for peripheral T-cell lymphomas. Pharmateca. 2026;33(6):54-63. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.6.54-63
Authors’ contribution: Concept and design: A.G. Kolgotina, L.A. Kramynin, L.V. Filatova. Data collection and processing – A.G. Kolgotina, S.S. Elkhova,
A.A. Zverkova, S.A. Volchenkov, N.S. Kolupaev, A.O. Eliseeva, E.N. Kodrul, I.S. Zyuzgin. Data analysis and interpretation – all authors. Manuscript preparation – A.G. Kolgotina, L.A. Kramynin, L.V. Filatova.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Keywords
peripheral T-cell lymphoma
first-line therapy
About the Authors
Anastasia G. Kolgotina, Oncologist, Department of Hematology and Chemotherapy with Intensive Care and Resuscitation Ward, National Medical Research Center for Oncology named after N.N. Petrova, Saint Petersburg, Russia; akolgotina@bk.ru, ORCID ID: https://orcid.org/0009-0001-2174-9083 (corresponding author)L.V. Filatova, National Medical Research Center of Oncology named after N.N. Petrov; North-Western State Medical University named after I.I. Mechnikov, Saint Petersburg, Russia
I.S. Zyuzgin, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
L.A. Kramynin, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
S.S. Elkhova, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
A.A. Zverkova, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
S.A. Volchenkov, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
N.S. Kolupaev, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
A.O. Eliseeva, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
E.N. Kodrul, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
T.Y. Semiglazova, National Medical Research Center of Oncology named after N.N. Petrov, Saint Petersburg, Russia
Similar Articles
